Obesity is associated with a great diversity of diseases including non-alcoholic fatty liver disease. Our recent report suggested that oat, rich in beta-glucan, had a metabolic-regulating and liver-protecting effect in an animal model. In this study, we performed a clinical trial to further confirm the effect of oat. Subjects with BMI ≧27 and aged 18–65, were randomly divided into a control (n = 18) and an oat-treated (n = 16) group, taking a placebo or beta glucan-containing oat cereal, respectively, for 12 weeks. Our data showed that consumption of oat reduced body weight, BMI, body fat and the waist-to-hip ratio. Profiles of hepatic function, including AST, but especially ALT, were useful resources to help in the evaluation of the liver, since both showed decrements in patients with oat consumption. Nevertheless, anatomic changes were still not observed by ultrasonic image analysis. Ingestion of oat was well tolerated and there was no adverse effect during the trial. In conclusion, consumption of oat reduced obesity, abdominal fat, and improved lipid profiles and liver functions. Taken as a daily supplement, oat could act as an adjuvant therapy for metabolic disorders.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Body mass index
Blood urea nitrogen
Free fatty acids
Fatty liver scores
High-density lipoprotein cholesterol
Low-density lipoprotein cholesterol
Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CWJ (1999) Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 341(15):1097–1105
Despres JP (2006) Is visceral obesity the cause of the metabolic syndrome? Ann Med 38(1):52–63
Friis LI, Aldenborg F, Jerlstad P, Rundstrom K, Bjornsson E (2004) High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 39(9):864–869
Gasbarrini G, Vero V, Miele L, Forgione A, Hernandez AP, Greco AV, Gasbarrini A, Grieco A (2005) Nonalcoholic fatty liver disease: Defining a common problem. Eur Rev Med Pharmacol Sci 9(5):253–259
Preiss D, Sattar N (2008) Non-alcoholic fatty liver disease: An overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 115(5):141–150
Stark AA (1991) Oxidative metabolism of glutathione by gamma-glutamyl transpeptidase and peroxisome proliferation: The relevance to hepatocarcinogenesis. A hypothesis. Mutagenesis 6(4):241–245
Grajeta H (1999) Effect of amaranth and oat bran on blood serum and liver lipids in rats depending on the kind of dietary fats. Nahrung 43(2):114–117
Maki KC, Beiseigel JM, Jonnalagadda SS, Gugger CK, Reeves MS, Farmer MV, Kaden VN, Rains TM (2010) Whole-grain ready-to-eat oat cereal, as part of a dietary program for weight loss, reduces low-density lipoprotein cholesterol in adults with overweight and obesity more than a dietary program including low-fiber control foods. J Am Diet Assoc 110(2):205–214
Sadiq Butt M, Tahir-Nadeem M, Khan MK, Shabir R, Butt MS (2008) Oat: Unique among the cereals. Eur J Nutr 47(2):68–79
Reyna-Villasmil N, Bermudez-Pirela V, Mengual-Moreno E, Arias N, Cano-Ponce C, Leal-Gonzalez E, Souki A, Inglett GE, Israili ZH, Hernandez-Hernandez R, Valasco M, Arraiz N (2007) Oat-derived beta-glucan significantly improves HDLC and diminishes LDLC and non-HDL cholesterol in overweight individuals with mild hypercholesterolemia. Am J Ther 14(2):203–212
Othman RA, Moghadasian MH, Jones PJ (2011) Cholesterol-lowering effects of oat beta-glucan. Nutr Rev 69(6):299–309
Peng CH, Chang HC, Yang MY, Huang CN, Wang SJ, Wang CJ (2012) Oat attenuate non-alcoholic fatty liver and obesity via inhibiting lipogenesis in high fat-fed rat. J Funct Foods, in press http://dx.doi.org/10.1016/j.jff.2012.08.003.
Liang RJ, Wang HH, Lee WJ, Liew PL, Lin JT, Wu MS (2007) Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes Surg 17(1):45–56
Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA 307(5):491–497
Charbonneau-Roberts G, Saudny-Unterberger H, Kuhnlein HV, Egeland GM (2005) Body mass index may overestimate the prevalence of overweight and obesity among the Inuit. Int J Circumpolar Health 64(2):163–169
Sanyal D, Mukhopadhyay P, Pandit K, Mukhopadhyay S, Chowdhury S (2009) Central obesity but not generalised obesity (body mass index) predicts high prevalence of fatty liver (NRFLD), in recently detected untreated, IGT and type 2 diabetes Indian subjects. J Indian Med Assoc 107(11):755–758
Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ (2006) Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 22(6):437–443
Esteghamati A, Noshad S, Khalilzadeh O, Khalili M, Zandieh A, Nakhjavani M (2011) Insulin resistance is independently associated with liver aminotransferases in diabetic patients without ultrasound signs of nonalcoholic fatty liver disease. Metab Syndr Relat Disord 9(2):111–117
Biorklund M, Holm J, Onning G (2008) Serum lipids and postprandial glucose and insulin levels in hyperlipidemic subjects after consumption of an oat beta-glucan-containing ready meal. Ann Nutr Metab 52(2):83–90
Wolever TM, Tosh SM, Gibbs AL, Brand-Miller J, Duncan AM, Hart V, Lamarche B, Thomson BA, Duss R, Wood PJ (2010) Physicochemical properties of oat beta-glucan influence its ability to reduce serum LDL cholesterol in humans: A randomized clinical trial. Am J Clin Nutr 92(4):723–732
Wood PJ, Beer MU, Butler G (2000) Evaluation of role of concentration and molecular weight of oat beta-glucan in determining effect of viscosity on plasma glucose and insulin following an oral glucose load. Br J Nutr 84(1):19–23
Gutkoski LC, El-Dash AA (1999) Effect of extrusion process variables on physical and chemical properties of extruded oat products. Plant Foods Hum Nutr 54(4):315–325
Inglett GE, Newman RK (1994) Oat beta-glucan-amylodextrins: Preliminary preparations and biological properties. Plant Foods Hum Nutr 45(1):53–61
We thank STANDARD Foods Co., Taiwan for providing all experimental diets.
Chiung-Huei Peng and Chau-Jong Wang contributed equally to this work and therefore, share the corresponding authorship.
About this article
Cite this article
Chang, H., Huang, C., Yeh, D. et al. Oat Prevents Obesity and Abdominal Fat Distribution, and Improves Liver Function in Humans. Plant Foods Hum Nutr 68, 18–23 (2013). https://doi.org/10.1007/s11130-013-0336-2
- Abdominal body fat
- Fatty liver